Evolus (EOLS)
(Real Time Quote from BATS)
$11.63 USD
+0.68 (6.21%)
Updated Jul 11, 2024 03:24 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EOLS 11.63 +0.68(6.21%)
Will EOLS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EOLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EOLS
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
EOLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
Green Thumb Industries Inc. (GTBIF) Surges 22.3%: Is This an Indication of Further Gains?
3 Top Stocks to Invest in for Amazing Earnings Acceleration
Other News for EOLS
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
Evolus announces submission of PMA to U.S. FDA for two Evolysse products
EOLS Crosses Below Key Moving Average Level
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
Evolus launches Nuceiva or botulinum toxin type A, in Spain